VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2022 | Updated results from CARTITUDE-1

Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, shares some updated results from a 27-month follow-up of the CARTITUDE-1 trial (NCT03548207), investigating the use of ciltacabtagene autoleucel (cilta-cel) in patients with relapsed/refractory (R/R) myeloma, drawing focus on the impressive response rates observed. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter